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Abstract (abridged) 
 
In this thesis, I will discuss my work toward discovering cyclic peptides against three 
large transmembrane proteins. The transmembrane proteins targeted in this study 
were chosen because they are only involved in protein-protein interactions and no 
drugs have been developed at this time to inhibit them from doing so. This is due to 
the fact that small molecules do not have a sufficient amount of possible contacts to 
get in the way of such interactions. Thus, peptides, which are slightly larger in size, 
are a great candidate drug class to fill this need for protein-protein interaction 
inhibitors. The RaPID (Random nonstandard Peptide Integrated Discovery) system 
has previously been shown to be a reliable platform for the discovery of cyclic 
peptides that bind with high affinity to enzymes and transporters as well as exerting 
varying degrees of inhibitory activity upon them. I used the RaPID system to generate 
macrocyclic peptides that bind to the three transmembrane proteins. 
  
In chapter 1, I discuss the current situation in drug discovery and the unmet 
challenges of generating drugs that block protein-protein interactions and how 
traditional drug discovery methods such as small molecule screens have not been 
adequate in addressing these challenges. The relevance and renewed focus on 
peptides as a drug class to meet these inadequacies of small molecules, and the 
superior features of in vitro display platforms such as the RaPID system compared to 
traditional high throughput small molecule screens are also discussed. 
  
In chapter 2, results of my selection for macrocyclic peptides that bind Plexins are 
described.  
  
In chapter 3, an attempt at discovering peptides with inhibitory activity against 
integrins is discussed.  
 
In chapter 4, a method to ribosomally synthesize fused tricyclic peptide libraries was 
developed and this is discussed in this section. 
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In chapter 5, selection of macrocyclic peptides that bind subunits of secretase 
complexes are described 
  
Chapter 6 is the conclusion of this thesis. Achievements and novel findings will be 
discussed. The implications of my findings and future possibilities stemming from the 
results of my studies will also be discussed       
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Chapters 1, 2, 3, 5 and 6 are not shown due to reasons 
involving patent applications. References of chapters 1, 2, 3, 
5 and 6 are included in this text. 
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Chapter 4 
 
Ribosomal synthesis of fused tricyclic peptides 
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Introduction 
In nature, several examples of polycyclic peptides exist, such as conotoxins, 
cyclotides and defensins1–3 and have a suprising variety of biological activities such 
as protease resistance, protein-protein interaction inhibition and, in some cases, oral 
bioavailability4,5. A method of ribosomally synthesizing such polycyclic peptides in a 
way that is compatible with mRNA display would be a very powerful tool in possibly 
discovering such peptides. However, these polycyclic peptides are often head-to-tail 
cyclized and contain multiple cysteines6. To be compatible with mRNA display, it is 
necessary to have a free C-terminus for puromycin attachment7. Additionally, 
scaffolds with multiple cysteines which have easily reversible disulfide bonds which 
make structural deconvolution a great challenge8. In an aim to develop a methodology 
to synthesize polycyclic peptides that are mRNA display compatible and have 
predictable yet complex topologies, the following method was established. 
 
Previous reports have shown that ribosomally synthesized peptides with an N-
terminal chloroacetyl group can be cyclized using the sulfhydryl group of downstream 
cysteines9. Additionally, it has been shown that there is some selectivity regarding the 
positioning of the cysteine in relation to the N-terminal chloroacetyl group10. When 
more than one cysteine is present, the N-terminal chloroacetyl group cyclizes with the 
foremost N-terminal cysteine. However, due possibly to steric reasons, a cysteine in 
the second amino acid position is not able to cyclize with the N-terminal chloroacetyl 
group. Therefore, an N-terminally chloroacetylated peptide containing a cysteine in 
the second amino acid position and three more arbitrarily spaced downstream 
cysteines would result in the formation of a cycle between the N-terminal 
chloroacetyl group and the second cysteine. The remaining unreacted first, third and 
fourth cysteines can then be reacted with 1,3,5-tris(bromomethyl)benzene (TBMB) to 
result in a fused tricyclic peptide. Such a methodology can be applied to the synthesis 
and screening of large fused tricyclic libraries. 
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Results and discussion 
Cyclizing peptides using an N-terminal chloroacetyl group and a downstream 
thiol is a very robust method of generating libraries of macrocyclic peptides9. 
Previous reports have identified that the N-terminal chloroacetyl group is not able to 
react with the sulfhydryl group of a cysteine at the second amino acid position10. 
Further, when multiple cysteines appear further downstream, the chloroacetyl group 
will cyclize with the foremost N-terminal cysteine. Thus if an N-terminally 
chloroacetylated peptide is designed to have a cysteine in the second amino acid 
position followed by three more randomly spaced cysteines, the cyclization will occur 
between the N-chloroacetyl group and the second cysteine leaving the first, third and 
fourth cysteines unreacted. Similar to the N-chloroacetyl group, TBMB can react with 
three sulfhydryl groups. Application of TBMB with the aforementioned peptide can 
result in a tricyclic peptide with a fused topology (Figure 1). Such a scaffold will 
make possible larger multicyclic peptides that still retain structural strain as well as 
the ability to interact with larger surface areas. 
 
Conditions of peptide tricyclization using TBMB would ideally not interfere 
with mRNA display steps as well maintain simplicity as to not reduce library diversity 
(i.e. buffer exchanges, changing tubes, etc). Several solvents (DMF, DMSO, 
acetonitrile, ethanol, methanol) were surveyed for their compatibility in reacting 
TBMB with in vitro translated peptides. In vitro transcription and translation of a 
DNA template L7WT and the addition of 40 mM TBMB in dimethyl formamide 
(DMF) following the reduction of disulfide bonds between cysteine residues with 18 
mM tris(2carboxyethyl)phosphine (TCEP) showed the cleanest and most reproducible 
post translational conversion of ribosomally synthesized monocyclic peptides to fused 
tricyclic peptides, detectable by an increase in 114.01 Da which corresponds to the 
addition of a mesitylene moiety (Figure 2a, b). To further confirm that this 114.01 Da 
shift was due to cyclization, MALDI-TOF MS/MS was used to compare the 
fragmentation pattern of monocyclic and proposed tricyclic peptides. The monocyclic 
sample should contain a long ‘tail’ which should produce various fragments upon 
collision induced decomposition. In contrast, if the TBMB treated monocyclic peptide 
is indeed tricyclized it will have only a short tail and will  
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not produce many fragments. MALDI-TOF MS/MS analysis of monocyclic L7WT 
showed several fragments which corresponded to various ‘tail’ regions (Figure 2c). 
However, as predicted, MALDI-TOF MS/MS analysis of TBMB treated L7WT did 
not produce any visible tail fragments which can be attributed to being tricyclized 
(Figure 2d). 
 
Although previous reports have determined this cyclization selectivity when 
multiple cysteines appear in the peptide sequence, the study was not performed with a 
peptide containing four cysteines. To demonstrate that this selectivity still exists with 
four cysteines a DNA template encoding a peptide containing a cysteine at the second 
amino acid position (Cys1) and three more downstream cysteines (from the N-
terminus: Cys2, Cys3, Cys4) all spaced seven amino acids apart was designed. 
Genetic code reprogramming via the FIT system was used to incorporate N-
chloroacetyl D-tryptophan at the first amino acid position. Further, genetic code 
reprogramming was used to incorporate L-lactic acid between Cys2 and Cys3. It is  
Figure 1. Reaction scheme of forming fused tricyclic peptides via ribosomal 
synthesis. Peptide translation initiated by an N-chloroacetylated amino acid 
and containing four downstream cysteines (with one of the cysteines in the 
second amino acid position) creates a monocyclic peptide. Reaction of the 
remaining three cysteines with tris(bromomethyl)benzene results in a fused 
tricyclic peptide. 
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established that the ribosome is able to catalyze ester bond formation11,12. Ester bonds 
hydrolyze much more readily relative to peptide bonds and therefore this peptide can  
be fragmented via alkaline hydrolysis and analyzed using MALDI-TOF MS to 
determine whether the initial cyclization event occurs between Cys2, Cys3 or Cys4 
Figure 2. Synthesis and MALDI-TOF MS/MS analysis of ribosomally 
synthesized monocyclic and tricyclic peptide L7WT. (a) Cyclization method of 
DNA encoded peptide L7WT. (b) MALDI-TOF MS analysis of monocyclic 
(monocyclic mobs = 3094.45 Da mcalc = 3094.45) and tricyclic (tricyclic mobs 
= 3208.50 Da mcalc = 3208.50) L7WT. (c) MALDI-TOF MS/MS fragmentation 
of monocyclic (Pm: parent ion) and tricyclic (Pt: parent ion) L7WT. Due to the 
high intensity of ions b1 and c1, expanded spectra are shown below. Several 
peaks corresponding to fragments of monocyclic L7WT were observed 
whereas only noise was observable in the expanded tricyclic L7WT spectra. 
(d) Observed fragmentation patterns of monocyclic and tricyclic L7WT. 
 
82""
(Cys1 is not able to react due, most likely, to steric reasons)10 (Figure 3a). In vitro 
translation of this peptide followed by MALDI-TOF MS analysis showed a single 
peak corresponding to the full length monocyclic peptide (Figure 3b). Upon alkaline 
hydrolysis with sodium carbonate, two peaks, one with a mass corresponding to an N- 
terminal fragment of a cyclization event with Cys2 and another with a mass 
corresponding to a peptide fragment downstream of the ester bond was observed. A 
small peak corresponding to the full length unhydrolyzed product was observed as 
well. Importantly, no peak corresponding to a full length hydrolyzed peak was 
observed confirming that even with a peptide containing four cysteines, the same 
cyclization selectivity is retained. DNA templates to encode the same peptide with 
ester bonds in differing positions all showed no peaks to contradict this cyclization 
phenomenon. 
 
Using the established tricyclization conditions, four model peptides were 
tested with 1, 2, 5, and 10 amino acids between each cysteine residue to examine what 
size scaffolds are possible (Figure 4). In vitro translation followed by the addition 
TBMB to each model peptide showed complete conversion of monocyclic peaks to 
tricyclic peaks. Additionally, three model peptides which together comprise all 
proteinogenic amino acids (with the exception of methionine which must be excluded 
to incorporate N-chloroacetyl D-tryptophan) to confirm that TBMB will not result in 
any unwanted side reactions with other residues. MALDI-TOF MS analysis of these 
peptides showed clean conversion of all three model-peptides from monocylic to 
tricylic peptides (Figure 4).  
 
To determine whether this tricyclization chemistry is compatible with the 
conditions of the RaPID system, a puromycin ligated mRNA template encoding a 
peptide containing three cysteines with 4 amino acids between each, an N-terminal N-
biotinyl-L-phenylalanine and a C-terminal GS linker was used to make two samples 
of peptide-mRNA fusions two be tested for recovery from streptavidin-conjugated 
magnetic beads. One sample was reacted with TBMB while DMF was added to 
another sample. These reacted and unreacted samples were first mixed with 
streptavidin-conjugated magnetic beads pre-blocked with biotin. Next, the peptide-
mRNA fusions were transferred to unblocked streptavidin-conjugated magnetic beads. 
The peptide-mRNA fusions were then removed from the unblocked  
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streptavidin-conjugated magnetic beads and the amount of cDNA recovered from 
both blocked and unblocked beads were determined via RT-PCR (Figure 5a). 
Approximately 0.05 and 0.6% of the unreacted peptide-mRNA fusion sample was 
recovered from the blocked and unblocked streptavidin-conjugated magnetic beads, 
respectively. For the reacted peptide-mRNA fusion samples, approximately 0.025%  
Figure 3. Confirmation of initial cyclization topology. (a) Fragmentation of 
ester bonds placed between various cysteines via L-lactic acid will result in 
different fragment sizes dependent on cyclization topology. (b) MALDI-TOF 
MS analysis of the fragments formed depending on ester bond positioning. All 
peaks support the formation of a cycle with cysteine 2. 
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and 0.35% was recovered from the blocked and unblocked streptavidin-conjugated 
magnetic beads, respectively. Although the amount of peptide-mRNA fusions 
recovered from the reacted samples were slightly lower than the unreacted, the 
difference was low and the fold difference between the unblocked and blocked beads 
were 10.2 for the unreacted peptide-mRNA fusions and 14.0 for the reacted peptide- 
mRNA fusions. These results show that the chemistry involved in the tricyclization of 
peptides by TBMB does not interfere with the steps required for the RaPID system. 
Conversely, to see if the tricyclization reaction is compatible with the conditions of 
the RaPID system the tricyclization reaction was carried out on a peptide after 
reagents for reverse transcription were added. MALDI-TOF MS analysis showed a 
peak with a mass corresponding to a tricyclized peptide which was shifted 114 MW 
from an unreacted sample confirming that this reaction can still proceed under 
conditions of the RaPID system (Figure 5b).  
Figure 4. Tricyclization of peptides with various size lengths and amino acid 
composition. (a) Schematic of tricyclized peptides in this study. (b) MALDI-
TOF MS analysis of monocyclic (black peaks) and corresponding tricyclic 
peptides (red peaks). Amino acid sequences are shown below each 
spectrum. (c) Calculated and observed masses of peaks in (b). 
85""
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Compatibility of tricyclization chemistry with the RaPID system. (a) 
N-terminally biotinylated peptide-mRNA fusions were with and without the 
addition of tris(bromomethyl)benzene were subjected to streptavidin 
conjugated magnetic beads to determine if cDNA can still be recovered. (b) 
MALDI-TOF MS analysis of peptide tricyclization under mock RaPID system 
conditions. Peaks representing the conversion of the monocyclic peptide (M, 
black peak) to a tricyclic peptide (T, red peak) was observed. M mobs = 
3625.56 Da (mcalc = 3625.46); T mobs = 3739.61 Da (mcalc = 3739.51)  
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Conclusion 
In this chapter I described my work in developing a general and robust method 
of producing fused tricyclic peptides of ribosomal origin. This method can be applied 
to ribosomally synthesize vast libraries of fused tricyclic peptides in an mRNA 
display compatible manner. The fused tricyclic topology allows one to design larger 
more complex peptides while still maintaining the structural strain seen in smaller 
monocyclic peptides which is established as a necessity for high binding affinity. This 
method is compatible with all proteinogenic amino acids with the exception of 
methionine which was excluded to allow genetic code reprogramming. This 
tricyclization method can be used for another attempt at selecting for peptides that 
bind α6β1-integrin and inhibit its interaction with laminin-511 (Chapter 3). 
Additionally, the larger size may make it applicable to select for tricyclic peptides that 
bind unstructured peptides. The human genome encodes for approximately 300 SH3 
domains which are composed of ~60 amino acids and no disulfide bonds13. These 
SH3 domains are capable of binding a short 5mer linear motif and thus tricyclic 
peptides of similar size may be used to bind a variety of linear peptides. This can open 
up doors for non-invasive binding of GPCR N-termini to add a fluorescence tag, 
highly selective histone tail binders for ChIP-seq14 or structural investigations of 
intrinsically disordered proteins15. 
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Materials and methods 
EnAsn-3'.R20-OMe: 5’-TGGCGGCTCTGACTGGACTC-3’ 
EnAsn-3'.R38: 5’-TGGCGGCTCTGACTGGACTCGAACCAGTGACATACGGA-3’ 
EnAsn-5'.F49:  
5’-
GTAATACGACTCACTATAGGCTCTGTAGTTCAGTCGGTAGAACGGCGGA-3’ 
EnAsn CAU.R43:  
5’-GAACCAGTGACATACGGATTNNNAGTCCGCCGTTCTACCGACT-3’ 
dFx.R46:  
5’-ACCTAACGCCATGTACCCTTTCGGGGATGCGGAAATCTTTCGATCC-3’ 
dFx.R19: 5’-ACCTAACGCCATGTACCCT-3’ 
3C-1-ext1: 
5’-TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACAT 
ATGTGCGGCTGCGGTTGCGGCTGC-3’ 
3C-1-ext2:  
5’-
TTTCCGCCCCCCGTCTTACGAACCTTTGCCGCTGCGATAATCGCAGCCGCA
ACCGCAGCC-3’ 
3C-2-ext1: 
5’-TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACAT 
ATGTGCGGCACCTGCGGTTCGTGCGGCCGTTGC-3’ 
3C-2-ext2:  
5’-
TTTCCGCCCCCCGTCTTACGAACCTTTGCCGCTGCGATAATCGCAACGGCC
GCACGAACC-3’ 
3C-5-ext1: 
5’-TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACAT 
ATGTGCGGCACCATTGCGAGCTGCGGTTCGTTTAGCCTGTGCGGCCGTGA
AGCG-3’ 
3C-5-ext2:  
5’-
TTTCCGCCCCCCGTCTTACGAACCTTTGCCGCTGCGATAATCGCACAGCGC
TTCACGGCCGCACAGG-3’ 
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3C-10 new FW  
5’-
TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGTG
CGGCACCATTGCGAAATTGCACGGTGCGATCTGCGGG-3’ 
3C-10 new RV1  
5’-
GGCTTGCGCAACGCTTCACGGCCGCAGTTACGGTGCTGTACCAAGGAACC
TTTCCCGCAGATCGCACCGTGC-3’ 
3C-10 new RV2 
5’-
TTTCCGCCCCCCGTCTTAGCGACCTTTACACTCCGAAGGCTTGCGCAACGC
TTCACG-3’ 
3C-5A FW  
5’-
TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGTG
TGGAACGAATGCAAGTTGCGGTAGTTACAGCTTATGTGGG-3’ 
3C-5A RV  
5’-
TTTCCGCCCCCCGTCTTAGGAGCCTTTGCCGCTACGGAAGTCACACAGCGC
TTTGCGCCCACATAAGCTGTAACTACCGCAACTTGC-3’ 
3C-5B FW  
5’-
TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGTG
TGGTACTGATCAAGCCTGCGGGAGTTGGTCTTTATGTGG-3’ 
3C-5B RV  
5’-
TTTCCGCCCCCCGTCTTACGACCCTTTACCCGAGCGCTTGTCGCAGAGGGC
TTCGCGTCCACATAAAGACCAACTCCCGCAGGC-3’ 
3C-5C FW  
5’-
TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGTG
CGGAACCATCGCCTCTTGCGGTAGCCACAGTCTCTGTGGC-3’ 
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3C-5C RV 
5’-
TTTCCGCCCCCCGTCTTAAGAACCTTTACCAGAACGTTTATCACAAAGAAC
AGGGCGGCCACAGAGACTGTGGCTACCGCAAG-3’ 
L7 WT FW  
5’-
TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGTG
TGGCACCATCGCAAGCAAACACTGCGGCTCCGCCCTTGTG-3’ 
L7 WT RV  
5’-
TTTCCGCCCCCCGTCTTATTTCGCATCACACGGGATGCGCAGAGCTTCACC
ACAGTGCTGCACAAGGGCGGAGCCGCAG-3’ 
L7 E1 FW 
 5’-
TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGTG
TGGCACCATCATGAGCAAACACTGCGGCTCCGCCCTTGTG-3’ 
L7 E2 FW  
5’-
TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGTG
TGGCACCATCGCAAGCAAACACTGCGGCTCCATGCTTGTGCAGCAC-3’ 
L7 E3 RV  
5’-
TTTCCGCCCCCCGTCTTATTTCGCATCACACGGGATGCGCAGCATTTCACC
ACAGTGCTGCACAAGGGCGGAGCCGCAG-3’ 
L7 E4 RV 
5’-
TTTCCGCCCCCCGTCTTATTTCATATCACACGGGATGCGCAGAGCTTCACC
ACAGTGCTGCACAAGGGCGGAGCCGCAG-3’  
3C-4FW: 
5’-
TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATATGTG
TTGGACGGGCGGTCCGCAGTGCGGCGGTTCCCATTATACG-3’ 
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3C-4RV: 
5’-"
TTTCCGCCCCCCGTCTTAAGACCCGCGACCACTACGATAATCACACGTATA
ATGGGAACCGCCGCACTG-3’ 
 
Synthesis of L-lactic acid dinitrobenzyl ester 
1 equivalent of L-lactic acid (29 mg) was reacted with 1.5 equivalents of 
dinitrobenzyl chloride (111 mg) with 2 equivalents of diethylamine (117 µl) in DMF 
(Total volume: 2 ml) and stirred for 12 hrs. The reaction was confirmed on TLC using 
1:1 hexane:ethyl acetate. The reaction was quenched with 350 µl 1 M HCl followed 
by the addition of 1 ml diethyl ether. The reaction was transferred to a 100 ml 
separating flask containing ~80 ml 50% diethyl ether aq. Contents were then mixed 
and the aqueous phase was drained. The remaining organic phase was brought to 80 
ml with 1 M HCl aq. and the aqueous phase was drained. This was repeated with H2O, 
saturated sodium bicarbonate and saturated NaCl. The remaining aqueous phase was 
further dehydrated with anhydrous MgSO4. The contents were filtered to remove 
MgSO4 and the evaporated on the rotovap followed by an oil pump vacuum. The 
product weighed ~120 mg at this point and was resuspended in 1 ml DCM. The 
product was run on two preparative TLC plates using 1:1 hexane:ethyl acetate as 
mobile phase. The single band was cut out, filtered and eluted with diethyl ether 
(~200 ml). The product remained a viscous liquid following evaporation and 53 mg 
remained at this point. The product was resuspended in 2 ml chloroform-D and 
subjected to NMR analysis (Figure 6). The NMR spectra showed impurities and 
following the testing of several mobile phase options, 1:1 hexane:acetone was used to 
re-purify the product via preparative TLC. This purification resulted in a clean NMR 
spectra of L-lactic acid dinitrobenzyl ester. 
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Synthesis of dFx, tRNAenAsnCAU and DNA templates. 
dFx was synthesized in the same manner as in Chapter 2 with the following 
exceptions: The extension step was performed with Fx-5’.F36 and dFx.R46. The 
following PCR amplification was performed with T7ex5.F22 and dFx.R19. 
tRNAenAsnCAU was synthesized in the same manner as in Chapter 2 with the following 
exceptions: The exception step was performed with EnAsn-5'.F49 and EnAsn 
CAU.R43. The first PCR amplification was performed with T7ex5.F22 and EnAsn-
3'.R38. The second PCR amplification was performed with T7ex5.F22 and EnAsn-
3'.R20-OMe. 
DNA templates for tricyclic peptide experiments (3C-1, 3C-2, 3C-5, 3C-10, 
3C-5A, 3C-5B, 3C-5C, L7WT, L7E1, L7E2, L7E3, L7E4 and 3C-4) were all 
synthesized as the above templates with primers named accordingly. 
 
Aminoacylation of tRNAs via flexizymes. 
tRNAfMetCAU was aminoacylated with cyanomethyl ester activated N-
chloroacetyl D-tryptophan or N-Biotinyl-L-phenylalanine which were synthesized in 
house as previously described. tRNAfMetCAU and eFx were mixed to a final 
Figure 6. 1H-NMR spectrum of L-Lactic acid dinitrobenzyl ester in D-chloroform 
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concentration of 25 µM with a MgCl2 concentration of 600 mM in 50 mM HEPES-
KOH pH 7.5. To this, the aforementioned cyanomethyl ester activated amino acids 
were added to a final concentration of 5 mM. After a 1 hr incubation on ice (or 2 hrs 
for N-Biotinyl-L-phenylalanine), the reaction contents were precipitated using an 
ethanol/sodium acetate mixture at pH 5.2. Pellets were kept dry and at -80ºC until use. 
tRNAenAsnCAU was aminoacylated with L-lactic-acid dinitrobenzyl ester using dFx by 
mixing both at a final concentration of 25 µM with a MgCl2 concentration of 600 mM 
in HEPES-KOH pH 7.5. To this, L-lactic acid dinitrobenzyl ester was added to a 
concentration of 5 mM and incubated on ice for 3 hrs followed by ethanol/sodium 
acetate precipitation.  
 
Ribosomal synthesis of tricyclic peptides. 
Using the FIT system, a monocyclic peptide is translated using a DNA or 
mRNA template encoding a peptide with a N-chloroacetylated amino acid in the first 
amino acid position, a cysteine in the second amino acid positions and three more 
arbitrarily spaced downstream cysteines. Following a 5 µl in vitro translation reaction, 
1 µl of H2O, 1 µl 150 mM tris(2-carboxyethyl)phosphine in 0.6 M HEPES KOH pH 
7.5 and 1 µl 40 mM tris(bromomethyl)benzene in DMF is added and incubated at 
25ºC for 1 hr. For MALDI-TOF MS or MS/MS analysis, 12 µl of HBS was added to 
each sample and desalted on a C-Tip column (AMR inc.) and eluted with a 50% 
saturated α-hydroxycinammic acid (Bruker Daltonics) solution of 80% acetonitrile 
0.5% sodium acetate. 
 
Translation and alkaline hydrolysis of L7 peptides. 
DNA templates encoding L7 peptides were synthesized using the methionine(-
) FIT system used in Chapter 2 with the following exceptions: L-lactic acid-
tRNAenAsnCAU was added to the translation mixture at a final concentration of 50 µM 
and translation was performed at 37ºC for 1 hr due to compensate for the slow 
formation of ester bonds by the ribosome. Following translation, any intramolecular 
disulfide bonds were reduced by treatment with tris(2-carboxyethyl)phosphine. 1 µl of 
1 M sodium carbonate was then added and the mixture was incubated at 37ºC for 1 hr 
to hydrolyze the ester bonds. Following hydrolysis, the sample was neutralized with 1 
µl 2% trifluoroacetic acid and desalted on a C-Tip column for MALDI-TOF MS 
analysis.
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